Objective To investigate the change of gamma-aminobutyric acid A (GABAA) receptor α1 subunit mRNA expression in nitroglycerin induced migraine rat model,thus suggesting the relationship between GABAA receptor and migraine.Methods Thirty adult female Sprague-Dawley (SD) rats were randomly divided into control group,migraine model group,sodium valproate-treated group,each of the last 2 groups was divided into the attacking group and intermission group.The model of migraine was established using Cristina method,once a week for 5 weeks.After the second injection,rats in sodium valproate-treated group were given sodium valproate(0.5 g/L,10 ml/kg) everyday,and those in control group and model group were given normal saline solution(10 ml/kg).After the fifth injection,at the second hour(attacking groups) or the fourth day(intermission groups and control group),reverse transcription-polymerase chain reaction was used to detect the expression level of GABAA receptor α1 mRNA in brainstem and trigeminal ganglion.Results The expression level of GABAA receptor α1 mRNA in modeling attacking group(1.50 ±0.13) was higher than any other group(control group:1.01 ±0.24,modeling intermission group:1.04 ±0.10,sodium valproate-treated attacking group:0.99 ± 0.22,sodium valproate-treated intermission group:0.72 ± 0.03),and it was significantly higher than modeling intermission group(x2 =9.490,P =0.009).There was no statistical difference between modeling group and any other group,and compared with control group,there was no statistical difference in sodium valproate-treated attacking group or intermission group.Conclusion The pathogenesis of migraine may be related to the expression level of GABAA receptor α1 mRNA.

Objective To investigate the current situation of the flow maternal health management in Jinyun ,and propose in‐tervention strategies according to the results .Methods Medical records of maternal in 18 confinements hospitals in Jinyun during October 2009 to September 2013 were selected and retrospectively analyzed ,including 16 ,430 cases of household registered mater‐nal and 1 ,301 non‐household registered maternal .Maternal health management of household registered maternal and non‐household registered maternal were compared;and maternal health care management satisfaction survey were implemented for 100 cases in each group .Results The household registration book built rate ,early build rates ,system management rate ,postpartum visit rates were 99 .2% (16 297/16 430) ,96 .7% (15 882/16 430) ,95 .8% (15 733/16 430) ,and 97 .7% (16 ,057/16 430) in household regis‐tered maternal ,while which were 74 .5% (969/1 301) ,64 .0% (832/1 301) ,59 .0% (768/1 301) and 65 .5% (852/1 301) in non‐household registered maternal ,the difference was statistically significant (P<0 .05);3 cases were not satisfied during the childbirth hospitalization in household registered maternal ,the dissatisfied rate was 1 .5% ,12 cases were not satisfied during the childbirth hospitalization in non‐household registered maternal ,the dissatisfied rate was 6 .0% ,the difference was statistically significant (P<0 .05) .Conclusion There is a considerable gap in maternal Jinyun flow maternal health management and local residence ,and we should strengthen the flow of maternal health care management ,making it a fair quality of health care management and opportuni‐ties ,thus contributing to local economic and social development .

The readjustment of the army establishments has resulted in the mergence of some sanatoriums into hospitals,which has given rise to a novel mode of management and offered a new opportunity for the development of sanatoriums.In the past four years since the mergence of our sanatorium into Nanjing General Hospital in 2004,we explored the mode of integrating recuperation with treatment and combined the resource advantages of ours with the technical superiority of the hospital,which led to an improvement of our competitive ability and comprehensive service and accordingly promoted the overall development of the sanatorium.

Objective to provide the evidence for inducing the SAP model in rats with proper concentration of sodium taurocholate.Methods 60 SD rats were divided into sham operated group, group of 1.5% in concentration, group of 3.5% in concentration and group of 5% in concentration randomly, while the SAP model was induced by the sodium taurocholate concentration of 1.5%,3.5% and 5% with the method of retrograde injection into the biliopancreatic duct.To calculate the mortality of different groups, measure the serum amylase, tumor necrosis factor -α(TNF -α) and interleukin -6 (IL -6),and to observe the pancreatic pathological scores of HE staining in rats.Results The mortality in group of 5% in concentration has a significant ascending compared with group of 1.5% in concentration, while the serum amylase, tumor necrosis factor -α(TNF -α) , interleukin -6( IL -6), pathological score of hemorrhage and acinar necrosis in group of 5% in concentration have a significant ascending compared with group of 1.5% in concentration and group of 3.5% in concentration.Conclusions A better SAP model may be induced by sodium taurocholate with the concentration of 5% by the method of retrograde injection into the biliopancreatic duct, which may accord with the physiological and pathological manifestation of SAP.

Neoantigens, as the products of gene mutations in tumor cells, are specific antigen expressed on the surface of tumor cells. They can be the targets of immuno-cell therapies with high specificity and safety. Immunotherapies based on tumor neoantigens became the new research hotspot as results of the applications of genomic sequencing technologies and the development of neoantigens prediction techniques. In this paper, the applied prospect of neoantigens in hematological malignancies is discussed based on the research progress in the last few years and the relevant reports from the 59th American Society of Hematology Annual Meeting.

Due to the successful application of all-trans retinoic acid (ATRA) and arsenic, the treatment of acute promyelocytic leukemia (APL) with PML::RARA fusion gene has achieved great success. However, some patients are presented with APL phenotype in cellular morphology, immunophenotype, and gene expression profile, while PML::RARA is negative, which is known as atypical APL (aAPL). In aAPL patients, more than 20 fusion genes related to retinoic acid receptors have been reported. It has been discovered that all evaluable patients with RARG fusion genes and approximately half of those with rare RARA fusion genes are resistant to ATRA, however, the molecular mechanisms of this resistance remain poorly studied. Combining with the reports in the 65th American Society of Hematology Annual Meeting, this paper reports great progresses of the key pathogenesis of aAPL and ATRA resistance mechanisms.

FLT3 internal tandem duplication (ITD) mutations are common in acute myeloid leukemia and show an important significance in guiding prognostic stratification and targeted therapy. With the widespread application of high-throughput sequencing technology and the increased ability to analyze mutation sequences, it has been found that more than half of FLT3-ITD mutations are not just tandem duplications but are also accompanied by some complex situations such as the addition of non-template sequences. Recent studies have revealed the sequence characteristics, mutagenesis mechanisms and related clinical prognostic significance of FLT3 length mutations (FLT3-LM). FLT3-LM with added non-template sequences is formed by abnormally activated terminal deoxynucleotidyl transferase. These patients show different treatment responses and prognosis when treated with chemotherapy, targeted therapy, and allogeneic hematopoietic stem cell transplantation, which provides a new perspective to understand FLT3-LM mutations more accurately and provides proposals for FLT3-LM typing based on the mutagenesis mechanism. The new typing rules can better reflect the differences in biological characteristics of the disease and more accurately guide the prognostic stratification and development of individualized treatment for patients with FLT3-LM mutations.

OBJECTIVETo elucidate the relationship between azoospermia factor(AZF) microdeletion of Y chromosome and azoospermia, the exact breakpoint of a severe Y-chromosome deletion was determined according to the physical map of AZF.

METHODSMultiplex polymerase chain reaction was used to amplify fifteen sequence tagged sites (STS), namely sY82, sY84, sY86 in AZFa, sY124, sY127, sY128, sY133, sY134, sY143 in AZFb, sY239, sY242 sY254, sY255 in AZFc, and sY145, sY152 in AZFd; sex-determining region Y(SRY) was taken as an internal control. And then sY82,sY86,sY85,sY84 were further analyzed using the sample of the patient who had Y-chromosome deletion by G band analysis to map the breakpoint at molecular level.

RESULTSAll 15 STS and sY85 were amplified in positive control while only sY82, sY86 were amplified in the clinical sample, thus the breakpoint was found to be between sY86 and sY85.

CONCLUSIONThis study on the patient provided the direct biomolecular evidence of the exact breakpoint of the severe Y-chromosome deletion and established the deletion map of acrocentric chromosome. It also proved that the patient's azoospermia was due to the deletion of AZF.

Azoospermia ; diagnosis ; genetics ; Chromosome Breakage ; Chromosome Deletion ; Chromosomes, Human, Y ; genetics ; Humans ; Male ; Polymerase Chain Reaction ; methods ; Reproducibility of Results ; Sensitivity and Specificity

Objective: To investigate the clinical significance of monitoring ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia (ALL) after allogeneic stem cell transplantation (allo-HSCT) . Methods: Clinical data of 13 children received allo-HSCT in Peking University Institute of Hematology from May 2009 to March 2016 were retrospectively collected. The ETV6-RUNX1 gene was examined by real-time quantitative polymerase chain reaction (RQ-PCR) . The correlation between its expression level and the disease status was analyzed. Results: Of 13 enrolled ALL cases, the ETV6-RUNX1 expression of 7 patients converted to positive after transplant at a median time of 137 days (range, 28-270 days) . The expression level of the first positive sample was 0.034% (range, 0.004%-0.061%) . The duration from ETV6-RUNX1 positive to hematological relapse was 196 days (range, 28-666 days) . Four patients experienced relapse at a median time of 294 days (range, 104-803 days) after allo-HSCT. The ETV6-RUNX1 expression converted to positive prior to MRD. Patients with positive ETV6-RUNX1 gene expression pre-transplantation would be more likely to relapse. Conclusion Monitoring ETV6-RUNX1 by RQ-PCR could be used to evaluate MRD status after allo-HSCT. Patients with positive ETV6-RUNX1 after transplant had a poor prognosis.

OBJECTIVE: To detect fusion gene with pathological significance in a patient with refractory and relapsed acute B cell lymphoblastic leukemia (B-ALL) and to explore its laboratory and clinical characteristics. METHODS: Transcriptome sequencing was used to detect potential fusion transcripts. Other laboratory results and clinical data of the patient were also analyzed. RESULTS: The patient was found to harbor TCF3 exon 17-ZNF384 exon 7 in-frame fusion transcript. The minimal residual disease (MRD) has remained positive after multiple chemotherapy protocols including CD19-, CD22- targeted chimeric antigen receptor T cells immunotherapy. The patient eventually achieved complete remission and sustained MRD negativity after allogeneic hemopoietic stem cell transplantation (allo-HSCT). CONCLUSION Transcriptome sequencing can effectively detect potential fusion genes with clinical significance in leukemia. TCF3-ZNF384 positive B-ALL has unique laboratory and clinical characteristics, may not well respond to chemotherapy and immunotherapy, and is more likely to relapse. Timely allo-HSCT treatment may help such patients to achieve long-term disease-free survival. TCF3-ZNF384 positive B-ALL is not uncommon in pediatric patients but has not been effectively identified.
B-Lymphocytes ; Basic Helix-Loop-Helix Transcription Factors/genetics* ; Child ; Hematopoietic Stem Cell Transplantation ; Humans ; Laboratories ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy* ; Trans-Activators/genetics* ; Transcriptome